Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma

Thierry Facon, Ruben Niesvizky, Maria Victoria Mateos, David Siegel, Cara Rosenbaum, Sara Bringhen, Katja Weisel, P. Joy Ho, Heinz Ludwig, Shaji Kumar, Kenneth Wang, Mihaela Obreja, Zhao Yang, Zandra Klippel, Khalid Mezzi, Amanda Goldrick, Christina Tekle, Meletios A. Dimopoulos

Research output: Contribution to journalArticlepeer-review

Abstract

Frailty is most prevalent among elderly multiple myeloma (MM) patients, and frail patients have a higher risk of poor outcomes due to reduced performance status or comorbidities. This post hoc analysis assessed efficacy and safety of carfilzomib combinations in frail patients with relapsed and/or refractory MM from the phase 3 ASPIRE (carfilzomib [27 mg/m2]-lenalidomide-dexamethasone [KRd27] vs lenalidomide-dexamethasone [Rd]), ENDEAVOR (carfilzomib [56 mg/m2]-dexamethasone [Kd56] vs bortezomib-dexamethasone [Vd]), and ARROW (once-weekly carfilzomib [70 mg/m2]-dexamethasone [Kd70] vs carfilzomib [27 mg/m2]-dexamethasone [Kd27]) studies. A frailty algorithm incorporating age, Charlson comorbidity index, and performance status classified patients as fit, intermediate, or frail. Results are presented for frail patients (ASPIRE, n 5 196; ENDEAVOR, n 5 330; ARROW, n 5 141). In ASPIRE, median progression-free survival (PFS) (hazard ratio; 95% confidence interval) was 24.1 (KRd27) vs 15.9 months (Rd) (0.78; 0.54-1.12); median overall survival (OS) was 36.4 vs 26.2 months (0.79; 0.57-1.08). In ENDEAVOR, median PFS was 18.7 (Kd56) vs 6.6 months (Vd) (0.50; 0.36-0.68); median OS was 33.6 vs 21.8 months (0.75; 0.56-1.00). In ARROW, median PFS was 10.3 (once-weekly Kd70) vs 6.6 months (twice-weekly Kd27) (0.76; 0.49-1.16). In all 3 studies, rates of grade $3 treatment-emergent adverse events were consistent with those observed in the primary studies. The ASPIRE, ENDEAVOR, and ARROW primary analyses demonstrated favorable benefit-risk profiles with carfilzomib-containing regimens compared with controls. Across clinically relevant subgroups, including those by frailty status, consistent efficacy and safety were observed with KRd27, Kd56, and weekly Kd70, and treatment with these regimens should not be restricted by frailty status.

Original languageEnglish (US)
Pages (from-to)5449-5459
Number of pages11
JournalBlood Advances
Volume4
Issue number21
DOIs
StatePublished - Nov 10 2020

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma'. Together they form a unique fingerprint.

Cite this